GH Research cites higher development costs as driver of wider nine-month operating loss
GHRS•GH Research reported a nine-month loss of $46.56 million, compared with $34.12 million a year earlier, as research and development and general and administrative expenses increased. Third-quarter loss narrowed to $12.45 million from $14.02 million, and cash, cash equivalents and marketable securities totaled $350.6 million.
1. Nine-month results
GH Research reported a loss of $46.56 million for the nine months ended September 30, 2026, compared with $34.12 million in the same period a year earlier. Research and development expenses rose to $34.85 million from $27.38 million, driven by technical development, clinical development and employee costs. General and administrative expenses increased to $18.71 million from $16.62 million, primarily reflecting higher professional fees.
2. Third-quarter figures
Third-quarter loss narrowed to $12.45 million from $14.02 million, with lower development expenses and professional fees supporting performance. Cash, cash equivalents and marketable securities totaled $350.6 million. An April ordinary-share offering generated $111.2 million in net proceeds.
